Injecting hope

Published November 18, 2020
Mahir Ali
Mahir Ali

NOTWITHSTANDING the ludicrous antics of the prima donna in the White House, 2020 will go down in history primarily as the year of the pandemic.

We cannot at this point be entirely confident that it won’t be remembered merely as the first year of the coronavirus catastrophe. After all, millions across Europe have lately been obliged to return to their urban or suburban bunkers after the easing of previous restrictions led to a second wave of potentially deadly infections.

Patient numbers have also been surging across the United States and Russia, and badly hit countries such as India and Brazil do not so far appear to be approaching a turning point. Imran Khan, while acknowledging cases had quadrupled in the previous fortnight and advising precautions, has attributed his nation’s relative reprieve to Pakistan being “specially blessed”, compared with Iran and India.

One can only wish he would desist from using the kind of language that differs by barely a degree from the voices that construe every scourge or disaster as a manifestation of divine wrath. And while the cancellation of PTI rallies might be seen as a blessing, restricting wedding parties to 300 people hardly counts as a serious curb. Those are 300 potential vectors, after all. Other countries have whittled the number down to 10 or fewer.

‘There is no patent. Could you patent the sun?’

But never mind all that, there’s help on the way, not from the heavens but from laboratories in the US and Europe, and possibly elsewhere. Last week, a vaccine developed by the Germany-based BioNTech in collaboration with the pharmaceutical giant Pfizer was declared to be 90pc effective. This week the US-based Moderna upped the ante with a concoction with purportedly nearly 95pc efficacy.

Read: Is Pfizer’s vaccine the answer to Pakistan’s Covid-19 problem?

Dozens of other preventive formulas are being tested by a number of countries including India, Britain, Russia and China. Hopefully, some of them will prove useful in due course. None of the vaccines has so far been approved for mass delivery. The first such approval could be just weeks away, and by next spring there could be several vaccines to choose from.

The best-case scenario thus holds out great hopes for 2021. The early part of the year could potentially be a turning point. But perhaps only for some.

First of all, although Pfizer and Moderna’s share prices have no doubt shot up since their announcements, the mass efficacy of their vaccines remains to be tested. SARS-CoV-2 is a tricky customer, and could mutate to avoid the pitfalls placed in its way by the cleverest of scientists.

Hopefully, that will not come to pass. Yet, even assuming that Moderna and Pfizer/BioNTech — and perhaps Oxford/AstraZeneca and other candidates that will join them before long — are as effective as they claim, there are economic and logistical considerations that cannot be overlooked.

The concept of ‘vaccine nationalism’ has sporadically been discussed for months. Even in cases where a number of countries have pre-purchased millions of doses, which of them will be served first? How long will it be before any country has sufficient stocks to inoculate at least the more vulnerable segments of its population?

And what about countries that lack the resources to bulk-buy the vaccine, the vast majority of whose citizens cannot afford it either? Pfizer expects to charge $39 for the two doses required for immunity that may not last more than a year. Moderna declared in August that it expected to charge $32-$37 per dose. Even the cost of the Oxford/AstraZeneca variant, possibly as low as $5 per dose, could prove prohibitive for billions of people.

But even if sufficient doses can be manufactured at high speed and subsidised by most governments, there is the question of delivery. Pfizer’s vaccine needs to be refrigerated throughout at minus 80 degrees Centigrade, which obviously requi­res special arrangem­ents (at an extra cost, naturally). Moderna’s concoction requires far lower levels of refrigeration, but cannot survive for more than a few hours at room temperature.

One of the biggest achievements in 20th-century medical science was the invention in 1953 of a vaccine against poliomyelitis, the virus that causes polio, a disease that was killing thousands and crippling almost 20 times as many (including president Franklin D. Roosevelt) in the US alone. The day it was officially approved for use two years later, the legendary journalist Edward R. Murrow put a leading question to Dr Jonas Salk, the researcher behind it: who owns the patent? “Well, the people, I would say,” Salk responded. “There is no patent. Could you patent the sun?”

Seven decades later, hardly any journalists would even raise such a question, let alone expect a similar response. There is, of course, no contradiction between marvelling at the achievements of medical science while decrying the profit motive.

An effective fast-tracked Covid-19 vaccine indeed provides cause for excitement, but no one should mistake it for a universal silver bullet.

mahir.dawn@gmail.com

Published in Dawn, November 18th, 2020

Opinion

Editorial

18 May, 2022

SC on defections

THE judgement is monumental and will significantly influence Pakistani politics for years to come. After a nearly...
18 May, 2022

Karachi blast

THE frequency of urban terrorism incidents over the past few weeks in Karachi should send alarm bells ringing within...
18 May, 2022

Threats to Imran Khan

IT seems there is never a dull moment in Imran Khan’s life. First, it was a cabal of local and international...
Updated 17 May, 2022

Buyer’s remorse

It is strange to hear senior PML-N leaders lamenting the subsidies, yet not even coming up with a subsidy rationalisation plan.
17 May, 2022

Sikh traders’ killing

THE brutal murder of two Sikh traders in the outskirts of Peshawar on Sunday illustrates the vulnerability of...
17 May, 2022

Cholera outbreak

REPORTS of rising cases of cholera and acute watery diarrhoea in several areas are raising the spectre of a public...